Beam Therapeutics falls after patient death in early trial
** Shares of biotech firm Beam Therapeutics BEAM.O fall 3.30% to $23.56
** A patient with sickle cell disease has died due to respiratory failure in an early-to-mid stage trial of company's CRISPR-based cell therapy, BEAM-101, according to an abstract
** Respiratory failure was likely related to conditioning of a chemotherapy called busulfan, which is used to prepare patients for infusion
** The death occurred four months after infusion
** Company says eight patients have been dosed with BEAM-101
** "While the patient death is unfortunate, we see the event as highlighting the need for less-toxic preconditioning options" - William Blair
** Vertex VRTX.O and CRISPR Therapeutics' CRSP.BN Casgevy and bluebird bio's BLUE.O Lyfgenia is approved for the treatment of sickle cell disease, which is a group of inherited blood disorders
** BEAM's Q3 net loss was $96.7 million, or $1.17 per share, compared with $96.1 million, or $1.22 per share, a year ago
** BEAM stock down ~15% YTD
Reporting by Sriparna Roy in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
